Imavita | Partner in preclinical models research and imaging solutions
Choose the best preclinical approaches to:
- Better mimic the complexity of human disease mechanisms
- Enhance the success of drug R&D
At Imavita, we are an innovative preclinical CRO, specializing in advanced imaging and biomarker analysis.
We help pharma, biotech, and research labs assess the efficacy, disposition and safety of new therapies with
precise, non-invasive tools across in vivo, in vitro,
and ex vivo models.
Preclinical services to evaluate
Drug disposition and efficacy &Non invasive and quantitative imaging techniques
Discover our customized in vivo models designed to assess
efficacy/pharmacodynamics (PD),
drug disposition/pharmacokinetics (PK),
and non-GLP toxicity/safety
under conditions that closely mimic human physiology.
These models allow longitudinal studies while significantly reducing the number of animals included in studies, thanks to non-invasive imaging technologies, when applicable.
Take advantage of robust in vitro systems to explore the mechanisms of action of drug candidates and generate reliable preliminary data.
These models enable fast and ethical screening before moving to in vivo animal experimentation.
Ex vivo models (organ cultures, tissues explants) preserve the tissue architecture and microenvironment,
allowing predictive and accurate analysis of treatment responses while adhering to the 3Rs principles.
Imavita offers image analysis services dedicated to preclinical studies.
The goal is to extract quantitative data (tumor volumes, tissue density, signal intensity, etc…) and qualitative insights (treatment effect visualization, disease progression tracking).
The analysis integrates multiple imaging modalities (BLI, FRI, OCT, PET/CT, etc.) using adapted tools and custom reporting.
Imavita offers tailored R&D services for the development of preclinical models, imaging protocols, and specific analytical methods.
We support exploratory and collaborative projects from proof of concept to the optimization of translational tools.
Each study is designed in close alignment with defined scientific goals in various domains of drug R&D.
Imavita provides pharmacokinetic (PK) studies adapted to preclinical models to characterize the absorption, distribution, metabolism, and elimination of drugs.
Our approach combines non-invasive imaging, quantitative analysis, and tailored protocols to assess biodistribution or time-course drug exposure.
- Exploratory or targeted studies supporting early-stage development
- Optional integration with PD data and imaging biomarkers
Discover our customized in vivo models designed to assess efficacy, pharmacokinetics (PK), and non-GLP toxicity under conditions that closely mimic human physiology. These models allow for longitudinal studies while significantly reducing the number of animals used, thanks to non-invasive imaging technologies, when applicable.
Take advantage of robust in vitro systems to explore the mechanisms of action of drug candidates and generate reliable preliminary data. These models enable fast and ethical screening before moving to animal experimentation.
Our ex vivo models (organ cultures,, tissues explants) preserve the tissue architecture and microenvironment, allowing predictive and accurate analysis of treatment responses while adhering to the 3Rs principles.
Imavita offers image analysis services dedicated to preclinical studies. The goal is to extract quantitative data (tumor volumes, tissue density, signal intensity, etc.) and qualitative insights (treatment effect visualization, disease progression tracking).
The analysis integrates multiple imaging modalities (BLI, FRI, OCT, PET/CT, etc.) using adapted tools and custom reporting.
Imavita offers tailored R&D services for the development of preclinical models, imaging protocols, and specific analytical methods. We support exploratory and collaborative projects from proof of concept to the optimization of translational tools. Each study is designed in close alignment with your scientific goals.
Imavita provides pharmacokinetic (PK) studies adapted to preclinical models to characterize the absorption, distribution, metabolism, and elimination of compounds.
Our approach combines non-invasive imaging, quantitative analysis, and tailored protocols to assess biodistribution or time-course drug exposure.
- Exploratory or targeted studies supporting early-stage development
- Optional integration with PD data and imaging biomarkers
Precise evaluation by :
- Classical approach using unlabeled compounds
- In vivo imaging approach after labeling.
State of the art models of:
- Psoriasis
- Atopic dermatitis
- Acne
- Skin wound healing
- Alopecia
- Pemphigus vulgaris
Why choose Imavita as your preclinical CRO partner for research?
Benefit from personalized guidance and tailored solutions for your pathology testing model
Every study is designed directly with Imavita’s veterinarians and PhD scientists, who adapt the model, group sizes and readouts to your compound, mechanism and decision point rather than applying a fixed catalogue protocol.
Count on reliable and reproducible data
Our imaging readouts are characterized for intra- and inter-operator variability and validated against histology, and each report states the statistical method, group size (n) and variability for every endpoint.
Rely on advanced expertise for innovative solutions
Imavita’s founders bring more than 25 years of experience in preclinical models, PK/PD, biomarkers and imaging, and the team routinely develops new disease models, labeling strategies and imaging protocols when no validated model exists.
Accelerate your R&D
Longitudinal imaging gives a full time course from a single cohort, so efficacy, exposure and biodistribution data come out of one study instead of several terminal-time-point studies.
Take advantage of Research Tax Credit Accreditation
Imavita is accredited for the French Crédit d’Impôt Recherche (CIR), so French clients can include eligible outsourced study costs in their CIR claim, within the scheme’s ceilings.
Be responsible
All animal studies run under EU Directive 2010/63/EU after ethics committee review, and non-invasive imaging is used wherever it can replace terminal sampling, applying the 3Rs (Replacement, Reduction, Refinement) in practice.
Driving innovation in drug development with tailored preclinical services and cutting-edge imaging technologies.
«The team was very implicated in a challenging development of a specific dermatology model in skin healing.
Animals welfare was more than respected, and results were quickly released for dosage optimization modelling.»
S.D., Project leader PKPD
Europe-based Pharma company
Empowering biotech firms with advanced models and responsive solutions to accelerate R&D pipelines.
«Impressive turnover results with beautiful images permitted us to visually convince our investors in continuing the program on our chimeric biological candidate.
Quantification was a must for scientific advise.»
R.L., CSO
US-based Biotech company
Supporting academic and industrial research with specialized expertise and adaptable methodologies.
«The academic lab discovered an interesting small molecule for which pilot data were necessary to validate cancer efficacy.
Imavita was very efficient in implementing fast in vitro model for our specific needs.
In vivo data qualified our candidate for future tests.»
B.R., TTO Team Leader
France
Join leading pharmaceutical, biotech companies and R&D teams who trust Imavita for their
preclinical research needs.
A human three-layer skin explant model of Cutibacterium acnes infection: inflammation, matrix remodeling and adipose response
Key takeaways Imavita and DIVA Expertise infected human full-thickness skin explants (epidermis, dermis and subcutaneous fat) with Cutibacterium acnes by intradermal injection. Live bacteria persisted for 72 h,
A human three-layer skin explant model of Cutibacterium acnes infection: inflammation, matrix remodeling and adipose response
Key takeaways Imavita and DIVA Expertise infected human full-thickness skin explants (epidermis, dermis and subcutaneous fat) with Cutibacterium acnes by intradermal injection. Live bacteria persisted for 72 h,
- News
Impact of Microbiota on Animal Models: From Facility Health Status to Translational Insights
Key point: The microbiological health status of an animal facility (conventional, SPF, SOPF, germ-free or gnotobiotic) changes immune, inflammatory and metabolic baselines. In Imavita’s hands, it measurably shifts
Impact of Microbiota on Animal Models: From Facility Health Status to Translational Insights
Key point: The microbiological health status of an animal facility (conventional, SPF, SOPF, germ-free or gnotobiotic) changes immune, inflammatory and metabolic baselines. In Imavita’s hands, it measurably shifts
- News
Image-Enhanced PK: IMAVITA’s Key Learnings in Preclinical Models
Image-Enhanced PK: IMAVITA’s Key Learnings in Preclinical Models
- News